Cargando…

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines

Respiratory virus infections precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations, with most exacerbations due to rhinovirus infection. Both asthma and COPD exacerbations are not well controlled by steroid therapies, and there is a much research interest in finding impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Michael R., Facchinetti, Fabrizio, Civelli, Maurizio, Villetti, Gino, Johnston, Sebastian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777265/ https://www.ncbi.nlm.nih.gov/pubmed/26977295 http://dx.doi.org/10.1002/prp2.202

Ejemplares similares

CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice
por: Stellari, Fabio F., et al.
Publicado: (2019)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
por: Jolling, Koen, et al.
Publicado: (2019)

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
por: Singh, Dave, et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers
por: Mariotti, Fabrizia, et al.
Publicado: (2018)

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
por: Govoni, Mirco, et al.
Publicado: (2020)

Phosphodiesterase 4 inhibitors attenuate virus‐induced activation of eosinophils from asthmatics without affecting virus binding
por: Sabogal Piñeros, Yanaika Shari, et al.
Publicado: (2020)

Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases
por: Nguyen, Hoang Oanh, et al.
Publicado: (2023)

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
por: Facchinetti, Fabrizio, et al.
Publicado: (2021)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
por: Nguyen, Hoang Oanh, et al.
Publicado: (2022)

The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation
por: Nguyen, Hoang Oanh, et al.
Publicado: (2022)

The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils
por: Schioppa, Tiziana, et al.
Publicado: (2022)

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
por: Sivilia, Sandra, et al.
Publicado: (2013)

Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model
por: Stellari, Fabio, et al.
Publicado: (2015)

Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14(+) Monocytes
por: Glaser, Kirsten, et al.
Publicado: (2016)

Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2009)

In Vivo Imaging of Transiently Transgenized Mice with a Bovine Interleukin 8 (CXCL8) Promoter/Luciferase Reporter Construct
por: Stellari, Fabio Franco, et al.
Publicado: (2012)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
por: Singh, Dave, et al.
Publicado: (2010)

Impacts of anti‐inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation
por: Zheng, Xiao‐Fang, et al.
Publicado: (2021)

Natural Phosphodiesterase-4 Inhibitors with Potential Anti-Inflammatory Activities from Millettia dielsiana
por: Le, Vu Thi Thu, et al.
Publicado: (2023)

Enlightened Mannhemia haemolytica lung inflammation in bovinized mice
por: Stellari, Fabio Franco, et al.
Publicado: (2014)

Effect of GM6001 on the expression of syndecan-1 in rats with acute kidney injury and its protective effect on the kidneys
por: Zhang, Kunying, et al.
Publicado: (2020)

Synthesis of CHF(2)-substituted 3-azabicyclo[3.1.0]hexanes by photochemical decomposition of CHF(2)-pyrazolines
por: Zheng, Yang, et al.
Publicado: (2018)

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020)

Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
por: Martin, Clémence, et al.
Publicado: (2021)

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
por: Grundy, Seamus, et al.
Publicado: (2016)

Surfactant replacement therapy in combination with different non-invasive ventilation techniques in spontaneously-breathing, surfactant-depleted adult rabbits
por: Ricci, Francesca, et al.
Publicado: (2018)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

The Saccharomyces cerevisiae W303-K6001 cross-platform genome sequence: insights into ancestry and physiology of a laboratory mutt
por: Ralser, Markus, et al.
Publicado: (2012)

Reading Level and Suitability of Congestive Heart Failure (CHF) Education in a Mobile App (CHF Info App): Descriptive Design Study
por: Athilingam, Ponrathi, et al.
Publicado: (2019)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study
por: Beghé, Bianca, et al.
Publicado: (2013)

Physiological, Biochemical, and Biophysical Characterization of the Lung-Lavaged Spontaneously-Breathing Rabbit as a Model for Respiratory Distress Syndrome
por: Ricci, Francesca, et al.
Publicado: (2017)

Plasma-derived exosomes implement miR-126-associated regulation of cytokines secretion in PBMCs of CHF patients in vitro
por: Natrus, Larysa, et al.
Publicado: (2022)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
por: Dalamaga, Maria, et al.
Publicado: (2020)

Measuring dobutamine (Db) clearance during continuous hemofiltration (CHF)
por: Van der Linden, T, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_lg5uiu191o698u1me2gja889an